Anecortave (Alcon Laboratories).
Anecortave, an angiostatic steroid administered as a posterior juxtascleral depot, is under development by Alcon Laboratories Inc for the potential prevention and treatment of ocular diseases, in particular age-related macular degeneration.
Vinores
Stanely A
SA
825 Maumenee Building, Wilmer Eye Institute, Johns Hopkins University School of Medicine, 600 N Wolfe Street, Baltimore, MD 21287-9289, USA. svinores@jhmi.edu
D020533:Angiogenesis Inhibitors / Q000737:chemistry / Q000627:therapeutic use*; D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D017326:Clinical Trials, Phase III as Topic; D004345:Drug Industry / Q000331:legislation & jurisprudence / Q000379:methods*; D015507:Drugs, Investigational / Q000737:chemistry / Q000627:therapeutic use*; D006801:Humans; D011244:Pregnadienediols / Q000737:chemistry / Q000627:therapeutic use*
D020533:Angiogenesis Inhibitors; D015507:Drugs, Investigational; D011244:Pregnadienediols; C418047:anecortave acetate